Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Keytruda Is King, But Merck Faces Questions About Business Development

Oct 26 2018

• By Mary Jo Laffler

chess

Related Content

Medicare's Foreign Price Bench-marking Will Only Hurt Bad Negotiators, HHS's Azar Argues

Oct 26 2018

Merck & Co.’s Keytruda/Inlyta Combo Invades Kidney Cancer Territory

Oct 18 2018

Key Cancer Data To Be Unveiled At ESMO In Munich

Oct 10 2018

Zoetis raises $2.2bn in IPO but other pharma majors to retain animal health

Feb 04 2013

Merck's Keytruda Enjoys Clean Sweep In Lung Cancer, At Bristol's Expense

Apr 17 2018

Finance Watch: Lilly Completes Elanco Animal Health Spin-Out As New IPO Filings Keep Rising

Sep 21 2018

Merck To Build Case For Doravirine-Based HIV Products On Efficacy, Safety Differences

Aug 31 2018

First-Line Chemo Combo Data Help Merck's Keytruda Power Past Opdivo

Jul 30 2018

Related Companies

Merck & Co., Inc.

Eli Lilly and Company

Pfizer Inc.

Bristol Myers Squibb Company

Merck KGaA

AstraZeneca PLC

Eisai Co., Ltd.

Additional Topics

ImmunoOncology Sales & Earnings Business Strategies Companies Commercial Cancer BioPharmaceutical

More from Immuno-oncology

More from Anticancer

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window